Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14.
SELLAS Life Sciences (SLS) announces positive Phase 1/2 data from galinpepimut-S in combination with Keytruda streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.